One of the most recent pharmacological agents with proven benefits in DKD is the SGLT-2 blockers, which, although introduced initially as drugs to lower hyperglycemia in diabetes, were later demonstrated to decrease the progression of DKD and even heart disease. This evidence concerns the gene SLC5A2 and diabetic kidney disease.